Vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection due to Candida, is the second most common vaginal infection affecting women of reproductive age in the United States. An estimated 75% of women worldwide will have at least one episode of VVC in their lifetime, and 40-50% of those will experience multiple episodes.
Although frequently caused by Candida albicans, infections caused by fluconazole-resistant and non-albicans Candida strains, such as Candida glabrata, have been reported to be on the rise.
VVC can be associated with significant discomfort (pain, itching, burning), reduced sexual pleasure and activity, psychological distress (stress, depression, anxiety), embarrassment, reduced physical activity, and loss of productivity.
Though common, vaginal yeast infections are sometimes dismissed or ignored as not serious. VVC can be a debilitating condition associated with an estimated 1.4 million outpatient visits each year.
Fungi are evolving organisms that have increasingly become resistant to treatment with azoles.
of women in the United States experience at least one acute vaginal yeast infection in their lifetime1.
Reference: 1.Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339-e347.
Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
Phase 3b, open-label, multicenter study to evaluate the efficacy, safety and tolerability of oral ibrexafungerp as a treatment for complicated vulvovaginal candidiasis (VVC) in patients who have failed treatment with fluconazole, based on mycological and clinical outcomes.